Kyverna Therapeutics price target lowered to $12 from $13 at UBS
UBS lowered the firm’s price target on Kyverna Therapeutics (KYTX) to $12 from $13 and keeps a Buy rating on the shares. The company reported ...
Perspective Therapeutics management to meet with Oppenheimer
Meeting to be held in Denver on April 2 and in San Francisco on April 3 hosted by Oppenheimer.Light Up your Portfolio with Spark:Easily ...
DelveInsight Business Research, LLP: LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight
LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...
LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight
DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...